Pulmonary telerehabilitation and efficacy among discharged COVID-19 patients: Rational and design of a prospective real-world study

被引:4
|
作者
Lei, Jieping [1 ,2 ,3 ,4 ,5 ]
Yang, Lulu [2 ,3 ,4 ,5 ]
Wen, Geyi [2 ,3 ,4 ,5 ,6 ]
Qumu, Shiwei [2 ,3 ,4 ,5 ]
Ren, Xiaoxia [2 ,3 ,4 ,5 ]
Yang, Ting [2 ,3 ,4 ,5 ]
机构
[1] China Japan Friendship Hosp, Inst Clin Med Sci, Data & Project Management Unit, Beijing, Peoples R China
[2] China Japan Friendship Hosp, Ctr Resp Med, Dept Pulm & Crit Care Med, 2 East Yinghua Rd, Beijing 100029, Peoples R China
[3] Chinese Acad Med Sci, Inst Resp Med, 2 East Yinghua Rd, Beijing 100029, Peoples R China
[4] Natl Clin Res Ctr Resp Dis, 2 East Yinghua Rd, Beijing 100029, Peoples R China
[5] Natl Ctr Resp Med, 2 East Yinghua Rd, Beijing 100029, Peoples R China
[6] First Peoples Hosp Yunnan Prov, Dept Pulm & Crit Care Med, Kunming, Yunnan, Peoples R China
来源
CLINICAL RESPIRATORY JOURNAL | 2021年 / 15卷 / 11期
关键词
comparative effectiveness research; COVID-19; real-world study; SARS-CoV-2; telerehabilitation; REHABILITATION;
D O I
10.1111/crj.13422
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Introduction The novel coronavirus disease 2019 (COVID-19) could cause physical and psychological dysfunction in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients. Pulmonary telerehabilitation is strongly recommended due to the contagious nature of the disease, but its efficacy and benefit need to be comprehensively evaluated. Methods An 8-week pulmonary telerehabilitation programme is designed in a real-world and prospective manner, aiming to assess the efficacy of remote rehabilitation among discharged patients with COVID-19 from three designated hospitals in the epicenter of China (Wuhan City). The telerehabilitation programme includes physicians and physiotherapists remotely guided training (online) for 2 weeks, and patient self-managed rehabilitation (offline) for 6 weeks with assistance of information technology and digital device. The main rehabilitation intervention includes breathing exercise, respiratory muscle training, aerobic exercise, and resistance training. The primary outcome is 6-min walk distance, and secondly pulmonary function, respiratory muscle strength, physical activity, symptom, psychological status and quality of life, etc. will also be assessed. Patients will be followed up periodically at week two, four, eight after enrolment and at month one, three, six and 12 after the rehabilitation accomplished, respectively. Current study has been approved by the ethics committee of China-Japan Friendship Hospital and three participating centers in Wuhan City. Discussion We anticipate that the health status of discharged patients with COVID-19 could be improved through this systemic pulmonary telerehabilitation programme. The interdisciplinary remote mode of rehabilitation could be an optimal way in management of emerging respiratory tract infectious disease. Trial registration ClinicalTrials.gov, NCT04368793.
引用
收藏
页码:1158 / 1167
页数:10
相关论文
共 50 条
  • [31] COVID-19: THE REAL-WORLD HOSPITALIZED PATIENT EXPERIENCE
    Rasouliyan, L.
    Kumar, V
    Long, S.
    Rao, M. B.
    [J]. VALUE IN HEALTH, 2021, 24 : S116 - S116
  • [32] Leveraging Real-World Data in COVID-19 Response
    Cooner, Freda
    Liao, Ran
    Lin, Junjing
    Barthel, Sophie
    Seifu, Yodit
    Ruan, Shiling
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2023, 15 (03): : 582 - 595
  • [33] Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study
    Zhao, Qinqin
    Zheng, Bei
    Han, Bing
    Feng, Pinpin
    Xia, Zhongni
    Jiang, Hong
    Ying, Yin
    Zhu, Jun
    Fei, Cheng
    Xiang, Junlei
    Shen, Lingli
    Luo, Qiliang
    Wu, Yinhuan
    Wusiman, Ayiguzhali
    Xin, Chuanwei
    Zhang, Meiling
    Li, Gonghua
    Li, Xiang
    [J]. INFECTIOUS DISEASES AND THERAPY, 2023, 12 (08) : 2087 - 2102
  • [34] Real-world effectiveness of oral antivirals for COVID-19
    Burdet, Charles
    Ader, Florence
    [J]. LANCET, 2022, 400 (10359): : 1175 - 1176
  • [35] Children with COVID-19: The real-world hospital experience
    Rasouliyan, Lawrence
    Kumar, Vikas
    Althoff, Amanda G.
    Long, Stacey
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 371 - 371
  • [36] Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study
    Qinqin Zhao
    Bei Zheng
    Bing Han
    Pinpin Feng
    Zhongni Xia
    Hong Jiang
    Yin Ying
    Jun Zhu
    Cheng Fei
    Junlei Xiang
    Lingli Shen
    Qiliang Luo
    Yinhuan Wu
    Ayiguzhali Wusiman
    Chuanwei Xin
    Meiling Zhang
    Gonghua Li
    Xiang Li
    [J]. Infectious Diseases and Therapy, 2023, 12 : 2087 - 2102
  • [37] Real-world prescription of anti-COVID-19 drugs in hospitalized patients with COVID-19 in Japan
    Shida, Haruka
    Komamine, Maki
    Kajiyama, Kazuhiro
    Waki, Takashi
    Maruyama, Hotaka
    Uyama, Yoshiaki
    [J]. PLOS ONE, 2024, 19 (01):
  • [38] Validation of real-world case definitions for COVID-19 diagnosis and severe COVID-19 illness among patients infected with SARS-CoV-2: Translation of clinical trial definitions to real-world settings
    Duh, Mei Sheng
    Nguyen, Catherine
    Rubino, Heather
    Herrick, Christopher
    Chang, Rose
    DerSarkissian, Maral
    Hsieh, Yichuan Grace
    Banatwala, Azeem
    Yu, Louise H.
    Belsky, Gregory
    Boyle-Kelly, Janet
    Cagan, Andrew
    Stangle, Bruce E.
    Cremieux, Pierre Y.
    Kolitsopoulos, Francesca
    Murphy, Shawn N.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 281 - 281
  • [39] Real-World Safety and Effectiveness of Remdesivir and Corticosteroids in Hospitalized Patients with COVID-19
    Caffrey, Aisling R.
    Liao, J. Xin
    Lopes, Vrishali V.
    LaPlante, Kerry L.
    Appaneal, Haley J.
    [J]. COVID, 2023, 3 (02): : 198 - 217
  • [40] A Real-World Evidence Framework for Optimizing Dosing in All Patients with COVID-19
    Peck, Richard W.
    Weiner, Daniel
    Cook, Jack
    Robert Powell, J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (05) : 921 - 923